Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

About this update from Cybin, Inc.

[{"type":"text","content":"Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032\n\n\n\n PALM BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) --\n \n\n FN Media Group\n \n\n\n News Commentary\n \n - Worldwide, there is a rising demand for neuropsychiatric disorder treatments which is expected to fuel the global markets for years to come. With expanding research and development efforts and a robust pipeline of novel medications, the neuropsychiatric disorders treatment landscape is evolving rapidly. Pharmaceutical companies are focusing on innovative drug therapies to meet the growing need for effective and affordable treatments. The market is primarily driven by the high incidence of mental illnesses, including depression and anxiety, and the rising awareness of these conditions. As a result, new treatment options are being developed, and drug-related activities such as clinical trials and drug approvals are intensifying. Recently an\n \n article\n \n on the 4th European Congress of Neurology and Neuropsychiatry website said that: “The global neuropsychiatric disorders and treatment market is on an upward trajectory, with a significant increase in demand for innovative solutions that cater to the growing burden of mental health conditions. In 2024, the market was valued at USD 130.5 billion, and by 2032, it is projected to reach USD 166.3 billion, growing at a compound annual growth rate (CAGR) of 10.20% from 2023 to 2032. This growth is fueled by continuous research, advancements in treatment, and heightened awareness of neuropsychiatric disorders.”   Active Companies active today in markets include:\n \n Cybin Inc.\n \n (NYSE: CYBN) (NEO: CYBN),\n \n COMPASS Pathways plc\n \n (NASDAQ: CMPS),\n \n Sage Therapeutics, Inc.\n \n (NASDAQ: SAGE),\n \n Mind Medicine (MindMed) Inc\n \n . (NASDAQ: MNMD) (NEO: MMED),\n \n atai Life Sciences\n \n (NASDAQ: ATAI).\n \n\n The article continued: “The growing global burden of neuropsychiatric disorders is a critical driver for the treatment market. With over 9.1 million annual deaths attributed to neurological diseases and an additional 8 million caused by neuropsychiatric conditions, this category represents a substantial public health challenge. These disorders contribute significantly to disability globally, with an estimated 461 million di...

More updates from Cybin, Inc.